Drug Product Development & Manufacturing
The successful development of oligonucleotide therapeutics requires not only optimized drug substance production but also robust formulation and drug product manufacturing strategies. Appropriate formulation design, delivery technology selection, and manufacturing processes are essential to maintain product stability, ensure consistent quality, and support clinical translation. By combining formulation expertise, analytical capabilities, and manufacturing experience, Protheragen helps partners develop stable and scalable oligonucleotide drug products from early development through clinical manufacturing.
Overview of Drug Product Development & Manufacturing
Drug product development represents a critical stage in the oligonucleotide development lifecycle, transforming purified drug substances into stable, safe, and clinically suitable pharmaceutical products. Unlike small molecule drugs, oligonucleotide therapeutics often present unique formulation challenges due to their large molecular size, high polarity, limited membrane permeability, and sensitivity to degradation.
A successful drug product strategy requires careful consideration of formulation composition, excipient selection, delivery technology, stability requirements, and manufacturing feasibility. Depending on the therapeutic modality and administration route, oligonucleotide drug products may be developed as aqueous injectable formulations, freeze-dried products, or advanced delivery systems such as lipid nanoparticles.
Our Services
From early-stage development to manufacturing readiness, oligonucleotide process development requires a comprehensive understanding of synthesis chemistry, purification strategies, analytical requirements, and scalability considerations. Protheragen provides integrated process development solutions tailored to different oligonucleotide modalities, helping clients establish robust and efficient manufacturing processes while supporting smooth progression toward clinical and commercial production.
Aqueous Injection Manufacturing
Aqueous injectable formulations are widely used for oligonucleotide therapeutics due to their straightforward manufacturing process and suitability for systemic administration. Developing a stable aqueous formulation requires optimization of formulation composition, pH, buffer systems, excipients, and storage conditions.
Protheragen provides aqueous injection development and manufacturing services to support the formulation and production of oligonucleotide drug products with optimized stability, quality, and manufacturing consistency.
Lyophilized Formulation Manufacturing
Lyophilization is an important formulation strategy for improving the long-term stability of oligonucleotide drug products. Freeze-dried formulations can enhance storage stability and support extended shelf life for molecules with limited stability in aqueous solutions.
Protheragen provides lyophilized formulation development and manufacturing solutions, including formulation optimization, freeze-drying cycle development, and stability evaluation.
LNP Formulation Manufacturing
Lipid nanoparticles (LNPs) have become an important delivery platform for nucleic acid therapeutics by improving molecular protection, cellular uptake, and tissue delivery. LNP-based formulation development requires optimization of lipid composition, particle characteristics, encapsulation efficiency, and manufacturing processes.
Protheragen provides LNP formulation development and manufacturing services to support RNA-based therapeutics, including formulation screening, process optimization, characterization, and scale-up development.
Core Drug Product Development Capabilities
Formulation Development
Development of optimized formulations by evaluating buffer systems, excipients, concentration, and physicochemical properties to achieve desired stability and performance.
Delivery System Development
Evaluation and optimization of advanced delivery platforms, including lipid nanoparticles and conjugation-based delivery strategies, to improve oligonucleotide delivery efficiency.
Process Development
Optimization of formulation processes, mixing parameters, sterile filtration, filling operations, and manufacturing conditions to establish reproducible production processes.
Analytical & Stability Support
Integration of analytical methods and stability studies to evaluate product quality attributes, formulation performance, and shelf-life characteristics.
Manufacturing Scale-up
Assessment of scalability and manufacturing readiness to support technology transfer and clinical-stage production.
Applications
The diversity of oligonucleotide therapeutics requires customized drug product strategies to address different molecular characteristics, delivery requirements, and clinical applications. Protheragen supports multiple oligonucleotide modalities and formulation approaches to advance innovative nucleic acid medicines.
Oligonucleotide-based medicines provide targeted approaches for regulating gene expression and controlling disease-related RNA pathways.
| Applications |
Supported modalities |
Splicing modulation
Mutation-specific gene regulation
mRNA expression control
Disease-associated RNA targeting |
Antisense Oligonucleotides (ASOs)
Phosphorodiamidate Morpholino Oligomers (PMOs)
Small Interfering RNAs (siRNAs) |
Many genetic disorders involve abnormal gene expression or RNA processing pathways. Oligonucleotide drug products provide opportunities for targeted molecular intervention.
| Applications |
Representative Modalities |
Splicing modulation
Mutation-specific gene regulation
mRNA expression control
Disease-associated RNA targeting |
Antisense Oligonucleotides (ASOs)
Phosphorodiamidate Morpholino Oligomers (PMOs)
Small Interfering RNAs (siRNAs) |
Oligonucleotide therapeutics are increasingly being explored in oncology due to their ability to regulate cancer-associated genes, modify immune responses, and target molecular pathways involved in tumor development.
| Applications |
Representative Modalities |
Oncogene regulation
Tumor-associated RNA targeting
Immune pathway activation
Cancer immunotherapy approaches |
Small Interfering RNAs (siRNAs)
Antisense Oligonucleotides (ASOs)
CpG Oligonucleotides
Lipid Nanoparticle (LNP)-based RNA Therapeutics |
- Cardiovascular & Metabolic Diseases
Oligonucleotide therapeutics have demonstrated significant potential in cardiovascular and metabolic disease areas by enabling selective regulation of disease-related genes involved in lipid metabolism and protein expression.
| Applications |
Representative Modalities |
Lipid metabolism regulation
Targeted gene silencing
Protein expression modulation |
Small Interfering RNAs (siRNAs)
Antisense Oligonucleotides (ASOs) |
- Vaccines and Immunotherapy
Advanced oligonucleotide technologies provide opportunities for immune modulation and next-generation vaccine development through targeted activation of immune pathways.
| Applications |
Representative Modalities |
Immune stimulation
Vaccine adjuvant development
Immune response modulation |
CpG Oligonucleotides
RNA-based Therapeutics
Lipid Nanoparticle (LNP)-enabled RNA Delivery Systems |
Why Choose Protheragen
- Integrated Oligonucleotide Development Platform
Protheragen provides integrated solutions covering drug substance, formulation development, analytical support, and manufacturing preparation, enabling seamless progression across the oligonucleotide development lifecycle.
- Flexible Formulation Strategies
Our platform supports diverse formulation approaches, including aqueous injection, lyophilization, and LNP-based delivery systems to address different therapeutic requirements.
- Modality-Specific Expertise
Experience with multiple oligonucleotide modalities, including ASO, siRNA, PMO, and CpG, enables customized development strategies based on molecular characteristics.
- Development-to-Manufacturing Support
From early formulation studies to process optimization and scale-up planning, Protheragen supports efficient transition toward clinical manufacturing.
- Quality-Focused Development
Integrated analytical evaluation and stability studies help ensure product consistency, reliability, and development readiness.
Successful oligonucleotide therapeutics require carefully designed formulations and reliable manufacturing processes to achieve clinical success. Protheragen combines formulation expertise, delivery technology development, analytical capabilities, and manufacturing support to help partners overcome drug product development challenges. Through flexible and scalable development solutions, our team enables the advancement of next-generation oligonucleotide medicines from early formulation studies toward clinical and commercial manufacturing. Contact us to accelerate the development of stable, scalable, and clinically ready oligonucleotide drug products.
